JP2018527903A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527903A5
JP2018527903A5 JP2018502692A JP2018502692A JP2018527903A5 JP 2018527903 A5 JP2018527903 A5 JP 2018527903A5 JP 2018502692 A JP2018502692 A JP 2018502692A JP 2018502692 A JP2018502692 A JP 2018502692A JP 2018527903 A5 JP2018527903 A5 JP 2018527903A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018502692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043712 external-priority patent/WO2017015622A2/en
Publication of JP2018527903A publication Critical patent/JP2018527903A/ja
Publication of JP2018527903A5 publication Critical patent/JP2018527903A5/ja
Pending legal-status Critical Current

Links

JP2018502692A 2015-07-22 2016-07-22 Gdf11結合タンパク質およびその使用 Pending JP2018527903A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195504P 2015-07-22 2015-07-22
US62/195,504 2015-07-22
US201662275068P 2016-01-05 2016-01-05
US62/275,068 2016-01-05
PCT/US2016/043712 WO2017015622A2 (en) 2015-07-22 2016-07-22 Gdf11 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2018527903A JP2018527903A (ja) 2018-09-27
JP2018527903A5 true JP2018527903A5 (enExample) 2019-10-17

Family

ID=57834686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502692A Pending JP2018527903A (ja) 2015-07-22 2016-07-22 Gdf11結合タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20180208648A1 (enExample)
EP (1) EP3324996A4 (enExample)
JP (1) JP2018527903A (enExample)
AU (1) AU2016297248A1 (enExample)
CA (1) CA3031430A1 (enExample)
WO (1) WO2017015622A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
WO2018112362A1 (en) * 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
US20200155481A1 (en) * 2017-05-03 2020-05-21 The Johns Hopkins University Intramuscular atovaquone for malaria prophylaxis
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
US12252531B2 (en) 2018-07-11 2025-03-18 Scholar Rock, Inc. Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
US20210299255A1 (en) * 2018-07-20 2021-09-30 Momenta Pharmaceuticals, Inc. Compositions of fcrn antibodies and methods of use thereof
UA130214C2 (uk) 2018-07-20 2025-12-24 Момента Фармасьютикалз, Інк. Фармацевтична композиція антитіл проти fcrn
WO2020027466A1 (ko) 2018-07-28 2020-02-06 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP7633259B2 (ja) * 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ TGF-βRII結合タンパク質
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001845A1 (en) * 1994-07-08 1996-01-25 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US20030167492A1 (en) * 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
AU765832B2 (en) * 1998-07-28 2003-10-02 Johns Hopkins University School Of Medicine, The Growth differentiation factor-11
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8952130B2 (en) * 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
US9700619B2 (en) * 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
WO2013148284A1 (en) * 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
US20150284455A1 (en) * 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
HUE052232T2 (hu) * 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US20200079850A1 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JP2021514973A5 (enExample)
JP2026040534A (ja) Fx活性化を促進する第x因子結合剤
HRP20120477T1 (hr) Nova anti plgf protutijela
CA2869438A1 (en) Humanized tau antibody
JP2024056687A5 (enExample)
JP2017536354A5 (enExample)
JP2020536532A5 (enExample)
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP2013091655A5 (enExample)
RU2012119788A (ru) Связывающие il-1 белки
JP2017535257A5 (enExample)
NZ585559A (en) Humanized antibodies against tl1a
JP2016527225A5 (enExample)
JP2016513664A5 (enExample)
JP2018510617A5 (enExample)
RU2010126078A (ru) Антитело против nr10 и его применение
JP2021502984A5 (enExample)
JP2022512234A5 (enExample)
JP2021511387A5 (enExample)
JP2022500455A5 (enExample)
JP2019528046A5 (enExample)
CN116514970A (zh) 靶向rankl的治疗性抗体
JP2018529672A5 (enExample)
AU2018214222B2 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies